Isoquercitrin isolated from Hyptis fasciculata reduces glioblastoma cell proliferation and changes beta-catenin cellular localization.

abstract：:This review focuses on the recent advances in chemotherapy of malignant gliomas, with special emphasis on the most common primary brain tumor in adults, glioblastoma. The demonstration of the superiority of concomitant and adjuvant temozolomide with standard radiotherapy over radiotherapy alone in patients with newly ...

journal_title：Anti-cancer drugs

authors： Soffietti R,Rudà R,Trevisan E

更新日期：2007-07-01 00:00:00

abstract：:Cancer invasion and metastasis are highly complex processes and a serine protease urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system has been postulated to play a central role in the mediation of cancer progression. Of note, malignant tumor urokinase-type plasminogen activator an...

journal_title：Anti-cancer drugs

authors： Nozaki S,Endo Y,Nakahara H,Yoshizawa K,Ohara T,Yamamoto E

更新日期：2006-11-01 00:00:00

abstract：:In the present study we investigated the enhancement of cytotoxicity of peritoneal macrophages induced by OK-432. Rats received an i.p. injection of OK-432 at doses of 0.1, 0.5 or 1.0 KE/rat. Two days later, rats were sacrificed and peritoneal macrophages were isolated. Then the number of macrophages was counted, and ...

journal_title：Anti-cancer drugs

authors： Huang Y,Xu Y,Yamagishi H,Hagiwara A

更新日期：2001-10-01 00:00:00

abstract：:We have synthesized and characterized doxorubicin (DOX)-loaded galactosylated gelatin nanovectors using in vitro and in vivo for targeting liver cells including hepatocarcinoma cells. Galactosylated and nongalactosylated gelatin nanovectors (GL-GN-DOX and GN-DOX) were spherical in shape and had mean sizes of about 95....

journal_title：Anti-cancer drugs

authors： Garg M,Madan J,Pandey RS,Sardana S,Katyal A,Chandra R

更新日期：2012-09-01 00:00:00

abstract：:Previous in vitro biochemical studies have revealed that the antitumor drug leinamycin causes oxidative DNA damage and DNA alkylation. However, it is still not clear whether the same mechanism(s) of action operate in cultured human tumor cells. Here, we evaluated the effects of leinamycin in the human pancreatic carci...

journal_title：Anti-cancer drugs

authors： Bassett S,Urrabaz R,Sun D

更新日期：2004-08-01 00:00:00

abstract：:The use of viability assays to assess the effect of antineoplastic agents on cell lines and tumor cells is an important investigative tool and may have clinical relevance. Such assays require very small quantities of drugs and it is the practice of many laboratories to freeze aliquots of drugs for use in these assays ...

journal_title：Anti-cancer drugs

authors： Hunter EM,Sutherland LA,Cree IA,Subedi AM,Hartmann D,Linder D,Andreotti PE

更新日期：1994-04-01 00:00:00

abstract：:Paeonol, a major phenolic component of Moutan Cortex, is known to have antitumor effects through an unknown mechanism. In this study, we tried to elucidate the anticancer effects of paeonol on human hepatocellular carcinoma (HCC) cell lines BEL-7404, SMMC-7721, and MHCC97-H in vitro. Using the 3-[4,5-dimethylthiazol-2...

journal_title：Anti-cancer drugs

authors： Chunhu Z,Suiyu H,Meiqun C,Guilin X,Yunhui L

更新日期：2008-04-01 00:00:00

abstract：:The anticancer drug candidates 1,3-dibenzyl-4,5-diphenyl-imidazol-2-ylidene gold(I) dimethylamino dithiocarbamate and 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl-1-thiolate derivative exhibited nanomolar in-vitro activity against prostate cancer cells advanced prostate cancer (PC3) and micromolar inhibition of mammalian...

journal_title：Anti-cancer drugs

authors： Walther W,Althagafi D,Curran D,O'Beirne C,Mc Carthy C,Ott I,Basu U,Büttner B,Sterner-Kock A,Müller-Bunz H,Sánchez-Sanz G,Zhu X,Tacke M

更新日期：2020-08-01 00:00:00

abstract：:Mistletoe extracts are frequently applied in adjuvant cancer treatment. The mistletoe lectins are especially suggested to mediate an antitumorous effect. During treatment with mistletoe lectin-rich extracts, anti-mistletoe lectin antibodies preferentially of the immunoglobulin G type are produced against mistletoe lec...

journal_title：Anti-cancer drugs

authors： Stein GM,Stettin A,Schultze J,Berg PA

更新日期：1997-04-01 00:00:00

abstract：:The efficacy of chemotherapy for advanced gastric cancer with palliative intent compared with supportive care alone is now widely accepted. However, the best choice of chemotherapy regimen for patients with advanced gastric cancer is still a matter of controversy and requires further investigation. This study is perfo...

journal_title：Anti-cancer drugs

authors： Cao W,Yang W,Lou G,Jiang J,Geng M,Xi W,Li H,Ma T,Jin Y

更新日期：2009-04-01 00:00:00

abstract：:The development of a new anticancer drug with a novel structure and unique mechanism of action is an important event, especially when the drug plays a clear role in improving the outcome for cancer patients. No drug fits this description better than Taxol. However, during the early phases of its development, there was...

journal_title：Anti-cancer drugs

authors： Wani MC,Horwitz SB

更新日期：2014-05-01 00:00:00

abstract：:Marine alkaloid meridianin G derivatives, substituted on the pyrimidine ring by aryl groups, were evaluated for their kinase inhibitory potencies and their in-vitro antiproliferative activities. The derivatives were tested toward a panel of nine protein kinases (KDR, IGF-1R, c-Met, RET, c-Src, c-Abl, PKA, CDK2/cyclin ...

journal_title：Anti-cancer drugs

authors： Rossignol E,Debiton E,Fabbro D,Moreau P,Prudhomme M,Anizon F

更新日期：2008-09-01 00:00:00

abstract：:Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 antibody drug, is the first-line therapy for human epidermal growth factor receptor 2-positive breast and gastric cancer. For breast cancer, the benefit of continuous treatment with trastuzumab after it becomes refractory to first-line therapy has ...

journal_title：Anti-cancer drugs

authors： Shu S,Yamashita-Kashima Y,Yanagisawa M,Nakanishi H,Kodera Y,Harada N,Yoshimura Y

更新日期：2020-03-01 00:00:00

abstract：:The primary aim of this randomized trial was to determine response rate and progression-free survival following chemotherapy in patients with platinum-resistant recurrent ovarian cancer, who had been treated according to an ATP-based tumour chemosensitivity assay in comparison with physician's choice. A total of 180 p...

journal_title：Anti-cancer drugs

authors： Cree IA,Kurbacher CM,Lamont A,Hindley AC,Love S,TCA Ovarian Cancer Trial Group.

更新日期：2007-10-01 00:00:00

abstract：:Targeting oncogenic signaling pathways by small molecules has emerged as a potential treatment strategy for cancer. reactivation of p53 and induction of tumor cell apoptosis (RITA) is a promising anticancer small molecule that reactivates p53 and induces exclusive apoptosis in tumor cells. Less well appreciated was th...

journal_title：Anti-cancer drugs

authors： Mobaraki RN,Karimi M,Alikarami F,Farhadi E,Amini A,Bashash D,Paridar M,Kokhaei P,Rezvani MR,Kazemi A,Safa M

更新日期：2018-10-01 00:00:00

abstract：:Imexon is an investigational anti-cancer agent, pharmaceutically formulated as a lyophilized solid for i.v. infusion requiring reconstitution and subsequent dilution in infusion fluid before infusion. Imexon contains a highly reactive aziridine ring in its structure, which limits its stability in aqueous solutions. In...

journal_title：Anti-cancer drugs

authors： den Brok MW,Nuijen B,Challa EE,Lutz C,Opitz HG,Beijnen JH

更新日期：2005-08-01 00:00:00

abstract：:Twelve patients received intrapleural instilments of the cytostatic agent mitoxantrone in a total dosage of 30 mg for locoregional palliative therapy of malignant pleural effusion. Effusion could be stopped for a mean period of 3.2 months in 11 patients. ...

journal_title：Anti-cancer drugs

authors： Torsten U,Opri F,Weitzel H

更新日期：1992-02-01 00:00:00

abstract：:Venetoclax is a first-in-class orally available, B-cell lymphoma (BCL)-2 inhibitor indicated for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) harboring the 17p deletion. We used a novel approach for evaluating venetoclax pharmacokinetics using only sparse sampling in 155 patien...

journal_title：Anti-cancer drugs

authors： Salem AH,Dunbar M,Agarwal SK

更新日期：2017-09-01 00:00:00

abstract：:A functionalized poly(amidoamine) (PAMAM) nanocarrier was designed and prepared to deliver anticancer drugs. The nanocarrier is a copolymer with a core-shell structure with 3.0 G PAMAM as the core and sequentially conjugated poly(2-(N,N-diethylamino)ethyl methacrylate) (pDEA) and methoxy-poly(ethylene glycol) 2000 (mP...

journal_title：Anti-cancer drugs

authors： Du L,Jin Y,Yang J,Wang S,Wang X

更新日期：2013-02-01 00:00:00

abstract：:Linking chemotherapeutic drugs to a macromolecular carrier system may enhance tumor targeting, reduce toxicity and overcome drug resistance mechanisms. As an elementary model to evaluate the pharmacological properties of macromolecular drug carrier systems we chose rat serum albumin (RSA) for carrier and methotrexate ...

journal_title：Anti-cancer drugs

authors： Stehle G,Wunder A,Sinn H,Schrenk HH,Schütt S,Frei E,Hartung G,Maier-Borst W,Heene DL

更新日期：1997-10-01 00:00:00

abstract：:In this study, we investigated the molecular mechanism of doxorubicin (dxr)-induced cytotoxicity on Jurkat cells - a model cell of human acute lymphoblastic leukemia - under normoxic (20% O2) and hypoxic (5% O2) conditions. Using in-cell western analysis, immunofluorescence, flow cytometry analysis, and biochemical in...

journal_title：Anti-cancer drugs

authors： Mendivil-Perez M,Velez-Pardo C,Jimenez-Del-Rio M

更新日期：2015-07-01 00:00:00

abstract：:Combretastatin A4 phosphate (CA4P) is a water-soluble prodrug of combretastatin A4 (CA4). The vascular targeting agent CA4 is a microtubule depolymerizing agent. The mechanism of action of the drug is thought to involve the binding of CA4 to tubulin leading to cytoskeletal and then morphological changes in endothelial...

journal_title：Anti-cancer drugs

authors： West CM,Price P

更新日期：2004-03-01 00:00:00

abstract：:The objective of this study was to determine the safety and efficacy of intravesical novantrone in refractory superficial bladder cancer. The eligibility criteria included proven carcinoma in situ or superficial transitional cell carcinoma of the bladder at stage Ta or T1 that was proven refractory to or in relapse af...

journal_title：Anti-cancer drugs

authors： Sharifi R,Lee M,Clayton M,Lamb D,Siami P,Strub M,Albert D,Sarosdy M

更新日期：1991-04-01 00:00:00

abstract：:To investigate the apoptotic mechanism of triple-negative breast cancer (TNBC) cells induced by gefitinib and PI3K inhibitor SF1126. MDA-MB-231, MDA-MB-436, and MCF-7 cells were incubated with 0.1 μmol/l gefitinib, 1 μmol/l gefitinib, 10 μmol/l gefitinib, 1 μmol/l SF1126, 0.1 μmol/l gefitinib+1 μmol/l SF1126, 1 μmol/l...

journal_title：Anti-cancer drugs

authors： Deng M,Wang J,Chen Y,Zhang L,Liu D

更新日期：2015-04-01 00:00:00

abstract：:We have examined the biological activity of keto-C-glycosides (KCGs), a new family of drugs displaying antiproliferative and cytotoxic properties on tumor cells. KCG1, the most powerful drug tested on epithelial derived neoplastic cells, was 25-125 times more cytostatic on epithelial cells than on lymphoma. By contras...

journal_title：Anti-cancer drugs

authors： Bennani-Baïti MI,Lafarge-Frayssinet C,Herscovici J,Monserret R,Antonakis K,Frayssinet C,Uriel J

更新日期：1992-08-01 00:00:00

abstract：:The type 1 insulin-like growth factor receptor (IGF1R) is overexpressed by many tumors, and mediates growth, motility and protection from apoptosis. Inhibition of IGF1R expression or function has been shown to block tumor growth and metastasis, and enhance sensitivity to cytotoxic drugs and irradiation. Thus the IGF1R...

journal_title：Anti-cancer drugs

authors： Bohula EA,Playford MP,Macaulay VM

更新日期：2003-10-01 00:00:00

abstract：:Targeted cancer chemotherapy is a novel approach developed for the specific delivery of anticancer drugs. Tumour targeting can be achieved by combining a chemotherapeutic agent with a targeting moiety that recognizes tumour-specific or highly expressed receptors on cancer cells. We used the gonadotropin-releasing horm...

journal_title：Anti-cancer drugs

authors： Manea M,Tóvári J,Tejeda M,Schulcz A,Kapuvári B,Vincze B,Mezo G

更新日期：2012-01-01 00:00:00

abstract：:Docetaxel has shown promise for the treatment of hormone-refractory prostate cancer and has become the standard of care. The flare phenomenon is a known entity in androgen-deprivation therapy of advanced prostate cancer and it has also been described in palliative chemotherapy of hormone-refractory prostate cancer. Th...

journal_title：Anti-cancer drugs

authors： Olbert PJ,Hegele A,Kraeuter P,Heidenreich A,Hofmann R,Schrader AJ

更新日期：2006-09-01 00:00:00

abstract：:The two major steps in our study on the treatment of skin carcinomas by photochemotherapy (PCT) were the development of a skin tumor model in Hairless mice by a chemical carcinogenesis and the use of fluorescence spectroscopy, a semi-quantitative and non-invasive method, in order to determine the time after i.p. injec...

journal_title：Anti-cancer drugs

authors： Bossu E,Padilla-Ybarra JJ,Notter D,Vigneron C,Guillemin F

更新日期：2000-02-01 00:00:00

abstract：:Multidrug resistance (MDR) is a major obstacle to successful chemotherapy for cancer; thus, novel MDR reversers are urgently needed. In the present study, we assessed whether two synthetic derivatives of 23-hydroxybetulinic acid, 3,23-O-diacetyl-17-1,4'-bipiperidinyl betulinic amide (DABB) and 3,23-O-dihydroxy-17-1,4'...

journal_title：Anti-cancer drugs

authors： Zhang DM,Li YJ,Shu C,Ruan ZX,Chen WM,Yiu A,Peng YH,Wang J,Lan P,Yao Z,Fung KP,Fu LW,Chen ZS,Ye WC

更新日期：2013-06-01 00:00:00